SALT
LAKE CITY, July 20, 2023 /PRNewswire/
-- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or
"Co-Dx"), a molecular diagnostics company with a unique, patented
platform for the development of molecular diagnostic tests,
announced today that it is hosting a booth at the American
Association for Clinical Chemistry (AACC) annual meeting and expo
held July 23-27, 2023 in Anaheim, CA.
Co-Dx will also be holding a special milestone presentation and
company update to discuss recent grant activity announced earlier
this month related to development of the upper respiratory
(flu/COVID/RSV), tuberculosis, and HPV tests on its upcoming Co-Dx
PCR Home platform. This new platform is currently undergoing
clinical evaluations in anticipation of its submission to the FDA
and an initial product launch for a COVID-19 test.
The presentation will take place in Room 213C at 11:00 AM local time on Tuesday, July 25, and will include Co-Dx CEO
Dwight Egan addressing the new grant
awards.
In addition to the Company's current and planned pipeline of
testing products, both for the new platform and for its existing
customer base of distributors and clinical laboratories around the
world, the Co-Dx booth will showcase the Co-Dx PCR Home which is
subject to FDA review and is not available for sale.
Attendees interested in learning more are invited to visit the
Company at Booth 827. Information about the AACC conference may be
found here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a
Utah corporation, is a molecular
diagnostics company that develops, manufactures and markets
state-of-the-art diagnostics technologies. The Company's
technologies are utilized for tests that are designed using the
detection and/or analysis of nucleic acid molecules (DNA or RNA).
The Company also uses its proprietary technology to design specific
tests for its Co-Dx PCR Home™ platform and to locate genetic
markers for use in applications other than infectious disease.
Forward-Looking Statements:
This press
release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA) that are subject to a number of risks and uncertainties.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release include statements regarding our anticipation of a
submission to the FDA and an initial product launch for a COVID-19
test following clinical trials for our new upcoming Co-Dx PCR Home
platform. Actual results may differ materially from those
contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. There can be no
assurance that any of the anticipated results will occur on a
timely basis or at all due to certain risks and uncertainties, a
discussion of which can be found in our Risk Factors disclosure in
our Annual Report on Form 10-K, filed with the Securities and
Exchange Commission (SEC) on March 16,
2023, and in our other filings with the SEC. The Company
does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release,
except as may be required by applicable securities laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-to-host-booth-and-discuss-recent-grant-awards-at-aacc-2023-in-anaheim-ca-301881839.html
SOURCE Co-Diagnostics